Tunlametinib, AG and Cetuximab for Advanced Pancreatic Cancer
Part of Cancer clinical trials.
This study tests a combination of three drugs as a first treatment for advanced pancreatic cancer. It aims to see if this combination can shrink or control the cancer, and it checks safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced pancreatic cancer confirmed by biopsy.
- You have not had any previous treatment for advanced disease.
- You are generally able to perform daily activities (ECOG 0-1).
- Your organs (kidney, liver, blood) must be in adequate condition.
- You are willing to use effective birth control if applicable.
- You can swallow oral medication and have no major stomach or bowel issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a new combination of two drugs for people with advanced pancreatic or colorectal cancer that has a specific genetic change called a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.